No Detail Found!

Analysis of doxorubicin and doxorubicinol in volumetric absorptive microsampling of breast cancer patients to monitordoxorubicin cardiotoxicity

Author(s)
Dian Fitri Chairunnisa Faculty of Pharmacy, University of Indonesia, Depok, West Java , Indonesia
Yahdiana Harahap Faculty of Pharmacy, University of Indonesia, Depok, West Java , Indonesia;Faculty of Military Pharmacy, Republic of Indonesia Defense University, Bogor, Indonesia
Maria Juanita Faculty of Pharmacy, University of Indonesia, Depok, West Java , Indonesia
Nadia Farhanah Syafhan Faculty of Pharmacy, University of Indonesia, Depok, West Java , Indonesia
Denni Joko Purwanto Dharmais Cancer Hospital, West Jakarta, Jakarta , Indonesia
Abstract
Backgrounadnd Objective: Doxorubicin s an anticancer therapy belongiton gth e anthracycline class, which has clinical activityi n breast cancer. Doxorubicin can cause cardiotoxic effects due to the formation of doxorubicinol asits main metabolite. The purpose of this study was to obtain the optimum sample preparation conditions for the analysis of doxorubicin in VAMS and as a form of therapeutic drug monitoring (TDM) in patients with cancer breasts. Materialasnd Methods: Analyze doxorubicin and doxorubicinol levels with Volumetric Absorptive Microsampling (VAMS)inpatients’ cancer breasts receiving doxorubicin intheir therapeutic regimenT.he sample was analyzed using Ultra Performance Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS). The method uses deep linear range concentrations of 8-200 ng/mL for doxorubicin and 3-100 ng/mL for doxorubicinol. Results: Multiple reaction monitoring (MRM) value set at m/z 544.22>396.9 for doxorubicin; m/z 546.22>398.9 for doxorubicinol and m/z 528.5>362.95 for daunorubicin. The LLOQ value obtained was 8 ng/mL for doxorubicin and 3 ng/mL for doxorubicinol with linearity of 0.9904 for doxorubicin and 0.9902 for doxorubicinol. Analysis results show doxorubicin levels were inthe range of 9.47 ng/mLt o 87.84 ng/mL and doxorubicinol range between 4.24 and 54.02 ng/mL. Conclusion: Dosage cumulative doxorubicin ranges between 47.93 and 346.09 mg/m? with this, the risk of cardiomyopathy in the patients surveyed is under 4%, according to the literature.
Publication Details
Page(s) 125-131
Published Journal: Pakistan Journal of Biological Sciences, Volume: 27, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
Breast cancer, LC-MS/MS, Doxorubicin, cardiotoxicity, doxorubicinol, volumetric absorptive microsampling
References
Gasjens T.,Briining D.,Taeger D. .2020 .Cancer risks of firefighters: A systematic review and meta-analysis of secular trends and region-specific differences. Int. Arch. Occup., : .
Environ . .. , 93 : 839-852.
Minotti G,Menna P.,Cairo G.,Gianni L. .2004 .AnthrMaoleccularyadcvanlcesianndpeharmsaco:logic developments in antitumor activity and cardiotoxicity. , : .
Pharmacol. Rev. . .. , 56 : 185-229.
Brunton L,Parker K. .2005 .Goodman and Gilman's The Pharmacological Basis of Therapeutics.. , : .
Pages .1984 .McGraw Hill Professional. , 9780071608916 : .
Luu A.Z,Chowdhury B.,Al-Omran M.,Teoh H.,Hess D.A.,Verma S. .2018 .Role of endothelium in doxorubicin-induced cardiomyopathy. JACC: Basic Transl. Sci,, 3 : 861-870.
Kip AE,Rosing H.,Beijnen J.H.,Dorlo T.P.C. .2017 .Volumetric absorptive microsampling (VAMS) as an alternto acotnvientvioenal dried blood spotsin the quantification of miltefosine in dried blood samples. , : .
Pharm J.,Fillet M.,M. M.,Mandrioli R.,Mercolini L,G L .2012 .European Medicines Agency guideline on bioanalytical method validation: What more is there to say? Bioanalysis,. Anal. Chim. Acta, 4 : 865-868.
Babaei N.,M.U. Salamci N.,S N.,CS. Ang P.,Wong N.S.,Lee EJD.,Chowbay B. .2008 .CBR7 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci., 99 : 2045-2054.
Gonzalez-Covarrubias V.,Zhang J.,Kalabus J.L.,Relling M.V.,Blanco J.G.,Dipiro J.T.,Schwinghammer T.L.,Dipiro C.V.,Handbook Pharmacotherapy,Blanco J.G,WM. Leisenring V.M.,Gonzalez-Covarrubias S.M.,Davies S.M.,White C.C.,Kavanagh T.J.,Chem T.J.,M. T.J.,Di L. .2017 .The role of carbonyl reductase 1 in drug discovery and development. Expert Opin. Drug Metab, 13 : 859-870.
Perez EA,Davidson N.E.,S. N.E.,Ewer M.S. .2003 .Congestive heart failure in patients treated with doxorubicin: Aretrospective analysis of three trials. Cancer, 97 : 2869-2879.
0

Citations

0

Downloads

41

Views